Business Context and Reporting Period
Company: Microbot Medical Inc. (MBOT)
Filing Type: Form 8-K (Current Report)
Date of Report: August 20, 2025
Principal Executive Offices: Hingham, MA
Reporting Period: This filing reports a specific event occurring on August 20, 2025, rather than a financial reporting period.
Key Financial Metrics
This Form 8-K does not contain financial statements, revenue, profit, cash flow, margin, debt, or liquidity data. The filing focuses exclusively on a regulatory and intellectual property milestone.
Material Changes and Events
- Patent Grant: The United States Patent and Trademark Office (USPTO) granted the Company a new patent covering a modular robotic surgical system. The system includes a base and a plurality of tool-receiver units that are independently and interchangeably attachable.
- Strategic Impact: The patent potentially enables the Company's LIBERTY device to be adapted for a wider range of endovascular procedures, which management states could substantially increase the Total Addressable Market (TAM).
- IP Portfolio Update: The Company's global intellectual property portfolio now includes 12 granted patents and 57 pending patent applications.
Guidance, Outlook, and Risks
Management Commentary: The Company views the patent grant as a significant expansion of its intellectual property protection in the United States for the LIBERTY system portfolio.
Forward-Looking Statements: The filing contains forward-looking statements regarding future regulatory milestones and market penetration. The Company explicitly states that actual results could differ from projections due to numerous factors and assumes no obligation to update these statements except as required by law.
Risks: Investors are directed to consult risk factors disclosed in other SEC filings. No specific new risks were detailed in this text beyond the standard disclaimer regarding the uncertainty of forward-looking statements.
Investor Verification Checklist
- Verify the specific claims of the granted patent in the full text of the USPTO document or the attached Press Release (Exhibit 99.1).
- Confirm the current status of the 57 pending patent applications and the 12 granted patents referenced in the filing.
- Review the Company's most recent 10-K or 10-Q filings for actual financial performance, cash runway, and liquidity metrics, as this 8-K contains no financial data.
- Assess the timeline and regulatory requirements for adapting the LIBERTY device to the new endovascular procedures mentioned.